Patients in the study will receive a 1 mg dose of V940 via intramuscular (IM) injection or a matched placebo ... with Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) in a phase 2 trial, with ...

The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology.

Libtayo shows robust growth in specific cancers, although it faces stiff competition in broader indications, highlighting Regeneron’s ability to develop blockbuster drugs. Regeneron appears ...

Subcutaneous immunotherapy injections work the same way as their intravenous counterparts — by changing or enhancing a person’s immune responses to cancer. Immunotherapy for cancer is a broad ...

One patient with Merkel cell carcinoma (MCC) achieved a durable complete response with 15 milligrams per kilogram (mg/kg) solnerstotug and Libtayo (cemiplimab) and remains on treatment at 42 or more ...

Despite these challenges, Regeneron's other drugs, particularly Dupixent and Libtayo, show promise for future growth and revenue generation. Given the current uncertainties and risks, I rate ...

The adverse event most commonly reported with Dupixent was injection site reaction. Results from BOREAS and the replicate NOTUS Phase 3 trial were published in The New England Journal of Medicine. In ...

The adverse event most commonly reported with Dupixent was injection site reaction. Results from BOREAS and the replicate NOTUS Phase 3 trial were published in The New England Journal of Medicine.

Dupixent is intended for injection under the skin (subcutaneous injection) and is given every other week. It can be given in a clinic or at home by self-administration after training by a healthcare ...

You should rotate these injection sites on your skin each time you inject insulin. There are different ways to take insulin, including syringes, insulin pens, insulin pumps, and jet injectors.

Philogen SpA reported a significant increase in its full-year 2024 revenues, reaching €77.5 million, a threefold rise compared to the previous year. Despite the impressive financial performance ...

Philogen SpA reported a significant increase in its full-year 2024 revenues, reaching €77.5 million, a threefold rise compared to the previous year. Despite the impressive financial performance, the ...